

Amendments to the Claims (Complete Listing of Claims)

62 1. (Currently amended) A method of treatment comprising administering to a patient, who is suffering from a disorder associated with a fungus of exogenous origin, ~~an agent of exogenous origin~~, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing the fungus agent to light capable of photoactivating protoporphyrin IX, wherein said disorder is characterized by the presence of lesions or cellular abnormalities having a tissue type selected from the group consisting of skin, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, the lining of the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity.

2. – 14. (Cancelled)

15. (Currently amended) A method according to claim 1, wherein said fungus is infectious.
~~agent is an infectious agent.~~

16. – 18 (Cancelled)

19. (Currently amended) A method of treatment, comprising administering to a patient, who is suffering from a disorder caused by a fungus of exogenous origin, ~~an agent of exogenous origin~~, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing said patient to light capable of photoactivating protoporphyrin IX, wherein said disorder is characterized by the presence of lesions or cellular abnormalities having a tissue type selected from the group consisting of skin, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, the lining of the group consisting of the mouth, pharynx, esophagus, stomach,

intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity.

20. – 23. (Cancelled)

24. (Currently amended) A method according to claim 19, ~~[[57,]]~~ wherein said fungus is infectious. ~~agent is an infectious agent.~~

25-27. (Cancelled)

28. (Original) A method according to claim 1, wherein the precursor of protoporphyrin IX is 5-aminolevulinic acid.

29. (Currently amended) A method according to claim 19, ~~[[57,]]~~ wherein the precursor of protoporphyrin IX is 5-aminolevulinic acid.

30. (Currently amended) A method according to claim 1, ~~[[18,]]~~ wherein said fungus is a member of the genus *Tinea*.

31. (Previously presented) A method according to claim 30, wherein said disorder is onychomycosis.

32. (Previously presented) A method according to claim 31, wherein said precursor is 5-aminolevulinic acid.

33. (Currently amended) A method according to claim 19, [[27,]] wherein said fungus is a member of the genus *Tinea*.

34. (Previously presented) A method according to claim 33, wherein said disorder is onychomycosis.

35. (Previously presented) A method according to claim 34, wherein said precursor is 5-aminolevulinic acid.

36. (Previously presented) A method of treatment comprising administering to a patient, who is suffering from a disorder associated with a fungus, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing the fungus to light capable of photoactivating protoporphyrin IX.

37. (Previously presented) A method according to claim 36, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

38. (Previously presented) A method according to claim 37, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

39. (Previously presented) A method according to claim 38, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.

40. (Cancelled)

41. (Currently amended) A method according to claim 39, [[40,]] wherein said fungus is a member of the genus *Tinea*.

42. (Previously presented) A method according to claim 41, wherein said disorder is onychomycosis.

43. (Previously presented) A method according to claim 42, wherein said precursor is 5-aminolevulinic acid.

44. (Previously presented) A method of treatment comprising administering to a patient, who is suffering from a disorder caused by a fungus, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing the fungus to light capable of photoactivating protoporphyrin IX.

45. (Previously presented) A method according to claim 44, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

46. (Previously presented) A method according to claim 45, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

47. (Previously presented) A method according to claim 46, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater, meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.

48. (Cancelled)

49. (Previously presented) A method according to claim 45, wherein said fungus is a member of the genus *Tinea*.

50. (Previously presented) A method according to claim 49, wherein said disorder is onychomycosis.

51. (Previously presented) A method according to claim 50, wherein said precursor is 5-aminolevulinic acid.
